- Psoriasis is a chronic, immune-mediated, inflammatory disease, affecting 125 million individuals worldwide.1
- In India, the prevalence of psoriasis varies from .44 to 2.8% and the incidence of Psoriatic arthritis is estimated to range from 7% to 42% among all psoriasis patients
New Delhi, March 14th: Eli Lilly, following approval from The Drug Controller General of India (DCGI) announced the launch of Copellor®(Ixekizumab) in India for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as treatment of adult patients with active psoriatic arthritis. A humanized IgG4 monoclonal antibody, Copellor®(Ixekizumab) is designed to specifically target IL-17A, a protein that plays a role in triggering and maintaining inflammation in psoriasis.
Vineet Gupta, Managing Director, Eli Lilly and Company – India & India Subcontinent said, “Our foray into the dermatology segment strengthens Lilly’s promise of bringing innovative medicines to India. Global Studies show that the impact psoriasis has on a patient’s quality of life is comparable to that of ‘serious’ diseases such as cancer and heart failure.5The availability of a new treatment like Copellor®(Ixekizumab) will now empower healthcare providers with another option for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as treatment of adult patients with active psoriatic arthritis, a huge unmet need in the country.”
Copellor®(Ixekizumab) is a prescription medicine to be used only on the advice of a dermatologist or rheumatologist and under medical supervision.
It is available in one strength of 80 mg/ml in a single dose prefilled autoinjector.
